Identification of Patients Who Require Two-Point Blood Sampling for the Peak and Trough Values Rather Than One-Point Blood Sampling for the Trough Value for the Evaluation of AUC of Vancomycin Using Bayesian Estimation
Pharmaceutical Research · 2024-11 · 41 (11) · 2161-2171
DOI: 10.1007/s11095-024-03781-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Research, online erschienen am 21.10.2024. Verfasst von Ayako Suzuki und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Showa University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-Ku, Yokohama-Shi, Kanagawa, 227-8501, Japan. Hauptthemen laut MEDLINE: Vancomycin, Drug Monitoring, Bayes Theorem, Area Under Curve. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: It is recommended to adjust the dose of vancomycin (VCM) with a target area under the concentration-time curve (AUC) of 400-600 μg·h/mL. Factors that affect the deviation between AUCs are estimated from the trough value alone and the trough and peak values using practical AUC-guided therapeutic drug monitoring (PAT) for vancomycin. In this study, factors that affect AUC were evaluated. METHODS: AUCs were estimated from a single trough value and trough and peak values, and the patients were classified into those who showed a 10% or greater deviation (deviation group) and those in whom the deviation was less than 10% (no-deviation group). Risk factors related to ≥ 10% deviation of AUC were identified by univariate and multivariate analysis. RESULTS: As a result of univariate and multivariate analysis of 30 patients in the deviation group and 344 patients in the no-deviation group, a creatinine clearance (CLcr) of ≥ 110 mL/min (odds ratio (OR) = 3.697, 95% confidence interval (CI) = 1.616-8.457, p = 0.002), heart failure with a brain natriuretic peptide (BNP) of ≥ 300 pg/mL (OR = 4.854, 95%CI = 1.199-19.656, p = 0.027), and the concomitant use of angiotensin converting enzyme inhibitor or angiotensin II receptor blocker (ACE-I/ARB) (OR = 2.544, 95%CI = 1.074-6.024, p = 0.034) were identified as risk factors of ≥ 10% deviation of AUC. CONCLUSIONS: Estimation of AUC by two-point blood sampling for the trough and peak values rather than one-point blood sampling for the trough value is suggested to improve the prediction accuracy in patients with enhanced renal function, severe heart failure, and patients using ACE-I/ARB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Showa University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-Ku, Yokohama-Shi, Kanagawa, 227-8501, Japan.
- Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-Ku, Tokyo, 105-8512, Japan. masaru.samura@gmail.com.
- Department of Pharmacy, Yokohama General Hospital, 2201-5 Kuroganecho, Aoba-Ku, Yokohama-Shi, Kanagawa, 225-0025, Japan. masaru.samura@gmail.com.
- Department of Pharmacy, Sapporo Medical University Hospital, 291 Nishi 16-Chome, Minami 1-Jo, Chuo-Ku, Sapporo-Shi, Hokkaido, 060-8543, Japan.
- Department of Pharmacy, Kyorin University Hospital, 6-20-2 Shinkawa, Mitaka-Shi, Tokyo, 181-8611, Japan.
- Department of Pharmacy, Tokyo Women's Medical University Hospital, 8-1 Kawada-Cho, Shinjuku-Ku, Tokyo, 162-8666, Japan.
Zitieren
APA
Suzuki, A., Samura, M., Ishigo, T., Fujii, S., Ibe, Y., Yoshida, H., Tanaka, H., Ebihara, F., Maruyama, T., Hamada, Y., Fujihara, H., Yamaguchi, F., Nagumo, F., Komatsu, T., Tomizawa, A., Takuma, A., Chiba, H., Nishi, Y., Enoki, Y., …, & Matsumoto, K. (2024). Identification of Patients Who Require Two-Point Blood Sampling for the Peak and Trough Values Rather Than One-Point Blood Sampling for the Trough Value for the Evaluation of AUC of Vancomycin Using Bayesian Estimation. Pharmaceutical Research, 41(11), 2161-2171. https://doi.org/10.1007/s11095-024-03781-4
Vancouver
Suzuki A, Samura M, Ishigo T, Fujii S, Ibe Y, Yoshida H, et al. Identification of Patients Who Require Two-Point Blood Sampling for the Peak and Trough Values Rather Than One-Point Blood Sampling for the Trough Value for the Evaluation of AUC of Vancomycin Using Bayesian Estimation. Pharmaceutical Research. 2024;41(11):2161-2171. doi:10.1007/s11095-024-03781-4
BibTeX
@article{Suzuki2024,
author = {Suzuki, Ayako and Samura, Masaru and Ishigo, Tomoyuki and Fujii, Satoshi and Ibe, Yuta and Yoshida, Hiroaki and Tanaka, Hiroaki and Ebihara, Fumiya and Maruyama, Takumi and Hamada, Yukihiro and Fujihara, Hisato and Yamaguchi, Fumihiro and Nagumo, Fumio and Komatsu, Toshiaki and Tomizawa, Atsushi and Takuma, Akitoshi and Chiba, Hiroaki and Nishi, Yoshifumi and Enoki, Yuki and Taguchi, Kazuaki and Matsumoto, Kazuaki},
title = {Identification of Patients Who Require Two-Point Blood Sampling for the Peak and Trough Values Rather Than One-Point Blood Sampling for the Trough Value for the Evaluation of AUC of Vancomycin Using Bayesian Estimation},
journal = {Pharmaceutical Research},
year = {2024},
volume = {41},
number = {11},
pages = {2161--2171},
doi = {10.1007/s11095-024-03781-4}
}
EUVIMED